(Q55463287)

12 July 2018

title

Bevacizumab does not increase the risk of remote relapse in malignant glioma. (English)

1 reference

12 July 2018

1 reference

7

1 reference

12 July 2018

Michael Weller

8

object named as

Michael Weller

1 reference

12 July 2018

10

Wolfgang Wick

1 reference

12 July 2018

9

Martin Bendszus

1 reference

12 July 2018

1

Antje Wick

1 reference

12 July 2018

Silvia Hofer

4

object named as

Silvia Hofer

1 reference

12 July 2018

author name string

Nils Dörner

2

1 reference

12 July 2018

Navina Schäfer

3

1 reference

12 July 2018

Sabine Heiland

5

1 reference

12 July 2018

Daniela Schemmer

6

1 reference

12 July 2018

publication date

1 March 2011

1 reference

12 July 2018

published in

Annals of Neurology

1 reference

12 July 2018

volume

69

1 reference

12 July 2018

issue

3

1 reference

12 July 2018

page(s)

586-592

1 reference

12 July 2018

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

cites work

1 reference

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

Bevacizumab and recurrent malignant gliomas: a European perspective.

21 January 2018

1 reference

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice

21 January 2018

1 reference

An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma

21 January 2018

1 reference

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival

21 January 2018

1 reference

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 January 2018

1 reference

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

21 January 2018

1 reference

A novel tool to analyze MRI recurrence patterns in glioblastoma

21 January 2018

1 reference

Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme

21 January 2018

1 reference

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

21 January 2018

1 reference

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.

21 January 2018

1 reference

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

21 January 2018

1 reference

Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy

21 January 2018

1 reference

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma.

21 January 2018

1 reference

Novel anti-angiogenic therapies for malignant gliomas

21 January 2018

1 reference

Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ANA.22336

1 reference

12 July 2018

PubMed ID

21446027

1 reference

12 July 2018